Effects of high-dose octreotide lar on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy

European Journal of Endocrinology

Volumn 164, Issue 3, 2011, Pages 341-347

  Mazziotti, Gherardo ^a   Porcelli, Teresa ^a   Bogazzi, Fausto ^b   Bugari, Giovanna ^a   Cannavò, Salvatore ^c   Colao, Annamaria ^d   Cozzi, Renato ^e   De Marinis, Laura ^f   Uberti, Ettore Degli ^g   Grottoli, Silvia ^h   Minuto, Francesco ⁱ   Montini, Marcella ^j   Spinello, Maurizio ^k   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j OSPEDALI RIUNITI   (Italy)

^k Respiratory Clinical Research   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HEMOGLOBIN A1C; OCTREOTIDE; SOMATOMEDIN C; ANGIOPEPTIN; INSULIN; METFORMIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; SOMATOSTATIN;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEMOGLOBIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; METABOLISM; MIDDLE AGED;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; SOMATOSTATIN;

EID: 79951979045     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0811     Document Type: Article

References (28)

1. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573. (doi:10.1056/NEJMra062453)
2. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
3. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA & Melmed S. Diagnosis and treatment of acromegaly complications. Journal of Endocrinological Investigation 2003 26 1242-1247. (Pubitemid 38324744)
4. Jaffrain-Rea ML, Moroni C, Baldelli R, Battista C, Maffei P, Terzolo M, Correra M, Ghiggi MR, Ferretti E, Angeli A, Sicolo N, Trischitta V, Liuzzi A, Cassone R & Tamburrano G. Relationship between blood pressure and glucose tolerance in acromegaly. Clinical Endocrinology 2001 54 189-195. (doi:10.1046/j.1365-2265.2001.01206.x)
5. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473. (doi:10.1210/jc.2005-0260)
6. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML,Wass JA & Giustina A. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740. (doi:10.1530/eje.1.02036)
7. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A & Chanson P. Impact of somatostatin analogs on the heart in acromegaly. A meta-analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 1743-1747. (doi:10.1210/jc.2006-2547)
8. Pereira AM, Biermasz NR, Roelfsema F & Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treatments in Endocrinology 2005 4 43-53. (doi:10.2165/00024677-200504010-00005)
9. Giustina A, Girelli A, Buffoli MG, Cimino A, Legati F, Valentini U & Giustina G. Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Research and Clinical Practice 1991 114 47-54. (doi:10.1016/0168-8227(91)90052-F)
10. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P & Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta analysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism 2009 94 1500-1508. (doi:10.1210/jc.2008-2332)
11. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, De Marinis L, Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M & Ghigo E. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European Journal of Endocrinology 2009 161 331-338. (doi:10.1530/EJE-09-0372)
12. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010 33 S11-S61. (doi:10.2337/dc10-S011)
13. Strowski MZ, Parmar RM, Blake AD & Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 2000 141 111-117. (doi:10.1210/en.141.1.111)
14. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F & Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. European Journal of Endocrinology 2006 155 73-78. (doi:10.1530/eje.1.02185)
15. Boehm BO & Lustig RH. Use of somatostatin receptor ligands in obesity and diabetic complications. Best Practice and Research. Clinical Gastroenterology 2002 16 493-509. (doi:10.1053/bega.2002.0320)
16. Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y, Schonbrunn A & Schaeffer JM. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic betacells. Endocrinology 1999 140 3790-3796. (doi:10.1210/en.140.8.3790)
17. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V & Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology 2003 59 492-499. (doi:10.1046/j.1365-2265. 2003.01876.x)
18. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T & Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 2000 52 549-555. (doi:10.1046/j.1365-2265.2000.00986.x)
19. Rizza RA, Mandarino LJ, Genest J, Baker BA & Gerich JE. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia 1985 28 70-75.
20. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G & Giordano DG. Clinical results of long-term slow-release lanreotide treatment of acromegaly. European Journal of Clinical Investigation 1997 27 277-284. (doi:10.1046/j.1365-2362.1997.1190659.x)
21. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ & del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. New England Journal of Medicine 1985 313 1576-1580. (doi:10.1056/ NEJM198512193132504)
22. Gola M, Bonadonna S, Mazziotti G, Amato G & Giustina A. Resistance to somatostatin analogs in acromegaly: an evolving concept? Journal of Endocrinological Investigation 2006 29 86-89.
23. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K & Melmed S. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
24. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177. (doi:10.1056/NEJM200004203421604)
25. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
26. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
27. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A & Giustina A. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 2007 10 227-232. (doi:10.1007/s11102-007-0037-7)
28. Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R & Ghigo E. Pegvisomant in acromegaly: why, when, how. Journal of Endocrinological Investigation 2007 30 693-699.